Hemogenyx Pharmaceuticals Share Discussion Threads

[luckyabbeygale] 10/10/2024 07:58

I just bought. Looking good for 2p here.

[saint in exile] 08/10/2024 10:59

Vlad is to blame for stating the trials were imminent from RNS 6th Sept.Now its gone to expected to be this year.No wonder the share has crashed is the CEO I'd giving out false info!

[luckyabbeygale] 08/10/2024 10:07

The more these drop the more I will comment since I find this incrediable in the way Hemo has now fallen to even lower again at 1.2p.
It is looking like they will not stop until they see someone jumping off a high rise building through the result of a big loss on their Hemo spreadbet.

[luckyabbeygale] 08/10/2024 07:43

No it is because I used to buy this share and I am grateful I did not have the funds since I would of fallen for it myself in heavily increasing my spread bets at up to 2.1p. Just like I would in any company if they had a placing at 3 times the price. Now anyone spread betting Hemo must be bankrupt at 1.25p.

[luckyabbeygale] 07/10/2024 14:37

Now millions lost at 1.3p. People have lost life changing amounts from Hemo spreadbetting.

[denholm elliott] 07/10/2024 14:08

You tweeting about this prediction Swazers?

[luckyabbeygale] 07/10/2024 08:07

Look at the rate traders are being stopped out at here.

[luckyabbeygale] 07/10/2024 07:40

1.35p now. So many rampers have sent people that was once well off into the poor house within two weeks on this stock.

[apotheki] 02/10/2024 16:10

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to children suffering from the otherwise largely incurable life-threatening diseases, AML and ALL, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in pediatric relapsed/refractory AML and ALL. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company, once again at a price very substantially above the Company's existing share price, demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

[apotheki] 02/10/2024 16:07

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukaemia and a subset of acute lymphoblastic leukaemia in children. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the Company to a significant value inflection point through the completion of its planned clinical trial."

[gah123] 02/10/2024 15:57

Onwards and upwards

[purple11] 02/10/2024 15:20

nothing to see here
move along lads.....

[saint in exile] 02/10/2024 14:52

Aw was the Prevail funding just a sleight of hand to get a placing away and provide enough funding until its completed?

[jaknife] 02/10/2024 13:45

gah123,

"Why don't you sell and move on then lol."

I'm going to assume that that's your way of saying that you agree with every one of my points.

If you take a look back in history you will see that HEMO's share price is frequently "spiked" in advance of fund raises. For example, look at that spike in January 2023. The shares peaked (intra-day) at 4.25p. Shortly thereafter they raised £4.1m at 2.5p per share.

Then in Feb this year the share price was spiked again, this time to 7.2p on an intra-day basis; by the end of Feb they had raised £3.3m at a price of 2p a share.

Today would represent the third time that HEMO's share price has been spiked in circumstances where they need to raise funds. If you can't spot the pattern and work out how to profit from that pattern then it's not my job to explain. However, buying the spike obviously isn't the right strategy!

JakNife

[gah123] 02/10/2024 13:31

Why don't you sell and move on then lol.

[jaknife] 02/10/2024 13:18

gah123,

"Even if you're correct which is highly questionable there could be another premium placing, grant, partner funding etc etc. We have enough for the trials - that's all that matters to me."

I am correct and my numbers are perfect, if you actually thought otherwise you would criticise the numbers rather than making vague noises about how they make you cry.

And HEMO doesn't have enough cash for the trials. Phase 1 trials costs loads. Take a look at Avacta as an example. They started Phase 1 trials in August 2021 and still haven't finished, meanwhile they've burnt £20m+ a year for the last three years on those trials.

1. HEMO only has enough cash to last to the end of this month.

2. The connected party deal that it's announced this morning won't bring any cash in until March next year (if at all).

3. HEMO hasn't even started its Phase 1 trials and probably doesn't have enough cash to pay the first bill!

4. A significant cash raise is needed, not a piddly silly £269k, which doesn't even keep the lights on for one month!

JakNife

[gah123] 02/10/2024 12:49

Even if you're correct which is highly questionable there could be another premium placing, grant, partner funding etc etc. We have enough for the trials - that's all that matters to me.

[jaknife] 02/10/2024 12:36

gah123,

"Not when you consider exceptionals and hemo have cut costs. Well it's just an estimate in any case but should atleast see them through to the end of the trials. I wouldn't rule out another premium placing after that so who cares."

You're making stuff up. There are no "exceptionals" in the interim figures and, to the extent that there was any "cost reduction", the accounts are clear that this is included in the numbers already.

Cash burn is c. $455 a month

HEMO only had $1,642,762 of cash as at 30 Jun,

$1,642,762 cash as at 30 Jun / $455 cash burn per month

= 3.7 months

30 June + 3.7 months = the end of October at the latest

JakNife

[gah123] 02/10/2024 12:33

Also company effectively indicating they are funded to atleast Mar next yr

[gah123] 02/10/2024 12:25

Not when you consider exceptionals and hemo have cut costs. Well it's just an estimate in any case but should atleast see them through to the end of the trials. I wouldn't rule out another premium placing after that so who cares.

[jaknife] 02/10/2024 12:21

gah123,

"Cash burn only 195k per month."

If we take the recent interim figures then you can see that in H1 the cash burn from operating activities alone was $2,350,820,

see:

They also had to pay $317,872 in lease costs so overall cash burn for the first six months of the year was $2,668,692.

That's about $445k a month and hence the trivial sum of money that has been promised for five/six months from now is about 24 days' worth of cash burn. If you look at the annual accounts you'll see that those show even higher cash burn.

"More than enough to get us through the end of the trial and then some"


HEMO only had $1,642,762 of cash as at 30 Jun, which is about enough to get HEMO to the end of this month. Hence you can see why they need to do something "creative" in order to get funds in ASAP.

And, to be clear, the clinical trials haven't even started yet, as set out clearly in the H1 accounts published just five days ago:

"The trials are expected to begin shortly at MD Anderson in Texas, one of the leading cancer treatment centers in the U.S. As shareholders know, we have been collaborating with the University of Pennsylvania Medical Center ("Penn") to conduct the trials at their facility."

Once the clinical trials do start then you can expect the cash burn costs to increase dramatically.

JakNife

[gah123] 02/10/2024 12:05

Biggest peers are valued atleast 5 times higher

[ashleyjv] 02/10/2024 11:40

Why are they paying nearly 3 times the share price?